Search results
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 5 days agoNovavax stock isn't a buy. Savvy investors are encouraged to buy a stock after it breaks out of a...
Novavax (NASDAQ:NVAX) PT Raised to $18.00
ETF DAILY NEWS· 3 days agoNovavax (NASDAQ:NVAX – Get Free Report) had its target price increased by Bank of America from $12.00 to $18.00 in a research report issued to clients and investors on Friday ...
Novavax seeks FDA nod for updated COVID-19 vaccine By Investing.com
Investing.com· 4 days agoNovavax , Inc. (NASDAQ: NASDAQ:NVAX) has announced its submission for an amended Emergency Use...
Is It Too Late to Buy Novavax Stock?
Motley Fool via Yahoo Finance· 5 days agoThose concerns are now alleviated as Novavax has agreed to refund up to $475 million. More recently, there was news that Novavax entered ...
3 Short-Squeeze Stocks Ready to Break the Chains of Bearish Sentiment
InvestorPlace· 15 hours agoIt was not long ago that Novavax (NASDAQ:NVAX) was among the stocks with high short interest. In the...
COVID summer guide: How to navigate symptoms, variants and vaccines this season
Yahoo Life· 5 days agoBut the good news is that the newly dominant variants don’t appear more likely to cause severe...
We Won't Solve Long COVID Until We Decide What It Is
Medscape· 1 day agoIs a slow recovery from COVID-19 the lingering effects of a bad infection or the start of a new syndrome?
COVID Variant KP.3 Surges to Dominance—Here's What You Need to Know
Health via Yahoo News· 6 days agoPer Zambrano, all three COVID vaccine manufacturers—Pfizer, Moderna, and Novavax—have said that...
FDA Tells Vaccine Makers to Target New COVID Variant for Fall
WFMZ Eastern Pennsylvania and Western New Jersey· 5 days agoCOVID vaccine makers will be advised to update their shots to target the KP.2 variant, an offshoot...
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
BioPharma Dive via Yahoo Finance· 5 days agoThe Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P....
